-
Font Size:
On January 7th, 2008, Genzyme (Nasdaq: GENZ) and Isis Pharmaceuticals (Nasdaq: ISIS) announced a partnership for the Isis cholesterol drug Mipomersen.
According to the deal, Genzyme will pay Isis $325 million upfront, with the potential for $825 million more in milestone payments as the drug progresses through stage 3 trials. In addition, Isis will receive another $750 million in milestone payments if the drug does well. This brings the grand total to a potential $1.9 billion for Isis. With a market capitalization of only $1.3 billion, Isis has some serious potential to earn intelligent investors lots of money.
The day the deal was announced, Isis stock surged more than 50% in after-hours trading, topping out at nearly $22 per share, up from $14.58 at market close. Since then, the stock has given up nearly all of its gains and is currently trading at $15.19; a mere 4.2% higher than before the deal was announced. Needless to say, I am shocked that the stock is not above $20 as we speak, and believe that it will be in the not-too-distant future.
I am not alone in thinking the stock is currently undervalued. Stanley Crooke, the CEO of Isis, said recently that he is “extremely disappointed” but doesn’t expect the current price will stay down for long.
While I agree with Mr. Crooke wholeheartedly, I also believe that he could do more to boost the stock. In fact, in looking at the past months’ insider buys at Isis, it appears as though no-one is buying the stock. Why is that? If this deal was so good, Mr. Crooke, prove you believe so by buying shares at market prices.
I know that for me, as an investor who is very enthusiastic about this deal, I cannot justify buying too much Isis stock until I see Mr. Crooke put some money where his mouth is. I hope to see this happen soon, so I can buy more without losing sleep.
In the interest of full disclosure, the author of this article owns shares of Isis Pharmaceuticals, and is soon to own more.
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
-
Editor's Picks
-
Most Popular
- Inside the Dubai Gold & Commodities Exchange: An Interview with Malcolm Wall Morris
- How the U.S. Financial Crisis Resembles Japan’s 'Lost Decade' - And How to Play it
- How the U.S. Financial Crisis Resembles Japan’s 'Lost Decade' - And How to Play It, Part II
- How High Leverage Has Brought Down the Whole Banking Industry
- These Days, Preferred Stocks Are Anything But Dull
- Free the Frozen Fed!
- Full list of Editor's Picks »
- Gas Lines Coming This Fall »
- Suncor, US Bancorp and MasterCard: Using a Stop Loss When Investing »
- Was That a Bottom? Should We Even Care? »
- Gold to Replicate Oil's Parabolic Move; 30-yr Treasury Yields to Soar »
- Earnings Preview: Citigroup »
- An In-Depth Look at Solar Stocks »
- You Knew the Short Squeeze Was Coming »
- The Death of Natural Gas »
- The Oil Bubble Will Meet the Same Fate as Tech, Housing »
- Apple Feels 'Max Pain' »
- Potash Heats Up: $1000 a Tonne? »
-
Long Ideas
-
Short Ideas
-
Cramer's Picks
- Thinking About Currency ETFs and Sovereign Debt
- ETF Pick of the Week: ProShares UltraShort Oil & Gas
- Google Proves Mortal: Opportunity Knocks?
- Amazon: New Kindle To Tap $5.5 Billion Textbook Market?
- Blockbuster - Profiting More Than the Profiteers
- Coal Stocks: Make Money in Picks and Shovels
- ConocoPhillips: Why the Sell-off?
- US Steel: Solid as They Come
- Two Water Transport Plays - Besides DryShips
- 'Dark Knight' Brings IMAX's Potential to Light
- Full list of Long Ideas »
- The SEC's Campaign Against Naked Shorting: Misguided or Right On?
- The Oil Bubble Will Meet the Same Fate as Tech, Housing
- Why I'm Shorting Apple Ahead of Earnings
- The Best Safe-Haven Investments, and Some Potential Threats
- Do Tell, Intel - Fast Money Recap (7/15/08)
- Separate Abusive Short Sellers from Those Who Play by the Rules
- Lehman: The End Game
- Freddie, Fannie and the French Revolution- Fast Money Recap (7/14/08)
- Meredith Whitney Slams Wachovia: Actionable Short Opportunity
- Chipotle Mexican Grill: Beware of Value Trap
- Full list of Short Ideas »
- For Everything, Wind - Stop Trading! (7/17/08)
- Market Lunacy Provides Opportunity - Cramer's Lightning Round (7/17/08)
- Market Rotation Underway - Cramer's Mad Money (7/17/08)
- Cox Not Watching - Cramer's Stop Trading! (7/16/08)
- Buy Boring Gas and Oil - Cramer's Lightning Round (7/16/08)
- Bear Market Rally - Mad Money Recap (7/16/08)
- The Great American Sellout - Cramer's Stop Trading! (7/15/08)
- Natural Gas Will Stay - Cramer's Lightning Round (7/15/08)
- The Windex Will Clean Up - Cramer's Mad Money (7/15/08)
- Fearful Day for Financials - Stop Trading! (7/14/08)
- Full list of Cramers Picks »
Most Popular Feeds
-
ETFs
-
US Market
-
Long Ideas
-
Alt. Energy
- Full list of feeds »
Hedge Fund Jobs
Job Seekers:
- Search jobs by category
- Get job alerts by email or live feed
- Apply online
Employers
- See all recruitment options
- Get applications online or by email




This article has 8 comments:
OR TAKE THE E OFF HIS LAST NAME
Do I buy back in or is this another pipe dream?
When you invest in Biotech you must have a ten year, or more, time frame. This is about the time it takes for a drug to get to market - if at all.
ISIS is the first biotech drug I have ever invested in and I did so because of the science. It is innovative and looks at an aspect of our DNA/RNA makeup that reveals a potential to stop disease by stopping or turning off certain protein production functions specific to a certain disease and thereby preventing or stopping the disease.
Who else beleives that they can do this?
These companies: EI Lilly, Alnylam, Ortho-Mcneil, Bristol Myers Squibb, J & J, Pfizer, Achaogen, Merck & Co., Antisense Therapeutics, Atlantic, Healthcare(UK), iCO, ImQuest Pharmaceuticals, OncoGenex, Sarissa, Archemix, Ercole Biotec, Rosetta Genomics, Santaris Pharma, Idera Pharma, Integrated DNA Tech., Drug Royalty USA, Inc., Eyetech Pharma and finally there is IBIS, which manufactures the T5000, which can identify bacteria and virus in human clinical samples and give an antidote or a cure in a few hours. This last was essentially purchased by Abbott last month.
Should you own ISIS - only if you have patience and the willingness to stick with a formidable bio-tech company that has cutting edge technology to cure and prevent disease from opthalmic to cancer.
Disclosure: writer has common and call options on ISIS.
Regards,
Ryan Freund
freundinvesting.com